RecruitingNot applicableNCT07546552
Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis
Studying Idiopathic pregnancy-associated osteoporosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Peter Humaidan
- Intervention
- Denosumab(other)
- Enrollment
- 100 target
- Eligibility
- 18 years · FEMALE
- Timeline
- 2025 – 2028
Study locations (1)
- Regionshospitalet, Skive, Midt Jylland 7800, Skive, Midt Jylland, Denmark
Collaborators
Herlev Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07546552 on ClinicalTrials.govOther trials for Idiopathic pregnancy-associated osteoporosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07508553Comparison of Bone Mineral Density in the Third Trimester Between Women in Singleton and Twin Pregnancies Using Questionnaires and REMS Densitometric ExaminationFondazione Policlinico Universitario Agostino Gemelli IRCCS
- ACTIVE NOT RECRUITINGNCT07031557Pregnancy and Lactation- Associated OsteoporosisParma University Hospital
See all trials for Idiopathic pregnancy-associated osteoporosis →